enGene Therapeutics Inc. Stock: price and insider trades · Canada

enGene Therapeutics Inc. is a listed company. Its insiders report their share dealings to SEDI. 17 insiders have disclosed 19 filings since 18 October 2025.

Every open-market trade in the period is a purchase: 1 purchase worth €8,763, from 1 insider, and not a single sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The buyers include 1 senior executive. Grossman William filed the largest purchase, €8,763, on 24 September 2026, which represents 0.0078% of the company's market value.

For context, the typical company on the same exchange (median of 2,144 companies) published 12 filings over the same period, against 19 filings here. The full history, which starts in 2026, counts 1 purchase against no sales.

The clock since the last published purchase (24 September 2026) now reads 24 days. Typically, a trade is published a median of 2 days after it takes place. Until a filing is published, the market cannot know about the trade.

This summary is built from SEDI disclosures alone and does not predict where the share price will go.